Windlas Biotech Ltd

Windlas Biotech Management Change

Windlass Biotech reports Mr. Ashok Kumar Windlass ceased as Executive Director, resigning for succession planning, effective 5 November 2026. He moves to Founder President, and Hitesh Windlass becomes Managing Director.

Windlas Biotech Results Update

Windlas Biotech reported H1 FY27 revenue of Rs 512 crore, up 18% YoY. Adjusted PAT rose 33% to Rs 50 crore for the half year.

Windlas Biotech Investor Presentation: Key Takeaways

H1FY27 revenue Rs 512 Cr (+18%), adj. PAT Rs 50 Cr (+33%, 9.7% margin); reported PAT flat at Rs 36 Cr on ESOP charges. CDMO-led growth; Plant-6 commercialised.

Windlas Biotech Q2 FY27 Results: Net Profit ₹18.1 Cr, Up 1.7% YoY

Windlas Biotech Ltd reported revenue from operations of ₹263.9 Cr (+18.7% YoY) and net profit of ₹18.1 Cr (+1.7% YoY) for Q2 FY27.

Key figure

Net profit ₹18.1 Cr · +1.7% YoY

Windlas Biotech Adverse Business Impact

Windlas Biotech disclosed a cyber security incident on 30 October 2026. It states no material impact on core operations, finances or business continuity.

Windlas Biotech Board Meeting Date

Windlas Biotech intimated that its Board meeting is scheduled for 5 November 2026 to consider unaudited standalone results for Q1 FY27. No monetary figure is disclosed in this advance notice.

Windlas Biotech Other Announcement

This quarterly shareholding pattern statement for Windlas Biotech Ltd, covering the period ended September 30, 2026, provides the company's equity ownership breakdown.